Tags » Mabthera

World's first cancer drug biosimilar approved in Europe

Celltrion’s Truxima, a near-copy of Roche’s MabThera, has become the world’s first approved cancer drug biosimilar. 

Having navigated the complex and stringent regulatory process for biosimilars, Truxima is now approved in all of the same disease indications as MabThera, which includes non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia (CLL) as well as inflammatory diseases rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. 272 more words

Pharma

Best Pharma Companies at a Glance: Roche

Hoffmann-La Roche (Roche) develops, manufactures and deliver innovative therapeutics and diagnostic instruments and tests.

The company operates through two business segments: Pharmaceuticals and Diagnostics. Pharmaceuticals division is further categorized on the basis of therapeutic areas into oncology, immunology, infectious diseases, ophthalmology, neuroscience and other therapeutic areas. 264 more words

Perspectives

Roche v. Biocad – Patent litigation likely to shape Russia’s IP landscape

The BRIC Wall Blog is pleased to present the following guest post by Ivan Burkov, Ph.D.

This post will examine recent patent litigation between Genentech (a U.S. 1,432 more words

Life Sciences